Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin

To improve understanding of the safety and efficacy of adding sitagliptin to treatment of patients with type 2 diabetes taking premixed insulin, data from patients using premixed insulin ± metformin (screening HbA1c ≥7.5% and ≤11%) in either of two clinical trials in which sitagliptin 100 mg once‐da...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2019-02, Vol.21 (2), p.408-411
Main Authors: Yu, Miao, Shankar, R. Ravi, Zhang, Ruya, Zhang, Ye, Lin, Jianxin, O'Neill, Edward A., Chen, Guojuan, Liu, Shu, Tu, Yingmei, Engel, Samuel S.
Format: Article
Language:English
Subjects:
Adult
Aged
Blood Glucose - drug effects
Blood Glucose - metabolism
Clinical trials
combination therapy for diabetes
Data processing
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - epidemiology
Double-Blind Method
DPP‐4 inhibitors
Drug Combinations
Drug Therapy, Combination
Female
Glycated Hemoglobin A - drug effects
Glycated Hemoglobin A - metabolism
Humans
Hypoglycemia
Hypoglycemia - chemically induced
Hypoglycemia - epidemiology
Incidence
incretin therapy
Insulin
Insulin - administration & dosage
Insulin - adverse effects
Male
Metformin
Metformin - administration & dosage
Metformin - adverse effects
Middle Aged
Multicenter Studies as Topic - statistics & numerical data
Patients
Randomized Controlled Trials as Topic - statistics & numerical data
Retrospective Studies
Sitagliptin Phosphate - administration & dosage
Sitagliptin Phosphate - adverse effects
Statistical analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To improve understanding of the safety and efficacy of adding sitagliptin to treatment of patients with type 2 diabetes taking premixed insulin, data from patients using premixed insulin ± metformin (screening HbA1c ≥7.5% and ≤11%) in either of two clinical trials in which sitagliptin 100 mg once‐daily or placebo was added to various formulations of insulin treatment, were analysed. In both trials, insulin doses were to remain stable throughout the 24‐week trial period. At week 24, the between‐group difference (sitagliptin ‐ placebo) in the least squares mean (95% confidence intervals) change from baseline in HbA1c in patients using premixed insulin was −0.43% (−0.58, −0.28), P
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.13517